NCT01524302

Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia

Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (CABP)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Gary E. Stein, Pharm.D. · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will further analyze the use of ceftaroline for CABP and compare its potential to eradicate bacterial pathogens to standard fluoroquinolone therapy. The enhanced spectrum of ceftaroline compared to levofloxacin may be further highlighted from this investigation.

Conditions

• Pneumonia, Bacterial
• Community-acquired

Interventions

Type	Name	Description
DRUG	Ceftaroline	600 mg Q12h
DRUG	Levofloxacin	750 mg QD

Timeline

• Start date: 2012-02-01
• Primary completion: 2014-05-01
• Completion: 2015-04-01
• First posted: 2012-02-01
• Last updated: 2016-04-12
• Results posted: 2016-04-12

Locations

1 site across 1 country: United States